Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06595030 · ClinicalTrials.gov registry record · NA

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

A NA study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
101
Enrollment target

NCT06595030: Completed NA study, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06595030 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 101 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06595030, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
101 participants
Enrollment target

Study Summary

Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.

Primary Outcome

The PSQI is used to measure sleep quality and is composed of 19 items that generate 7 component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction). Each subscale is scored 0 to 3. The sum of the 7 component scores yields a single global score with a full scale range of 0 to 21. A higher score indicates higher sleep disturbance.

Interventions

  • DEVICE Active Lighting Intervention
  • DEVICE Control Lighting Intervention

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2024-12-03
Est. Completion 2026-01-31
Phase NA

What the finished NCT06595030 record still lists

NCT06595030 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Active Lighting Intervention is the first listed.

NCT06595030 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06595030 about?

NCT06595030 is a clinical study titled "Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3". Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 par...

What is the current status of trial NCT06595030?

This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2024-12-03. Estimated completion is 2026-01-31.

What interventions are being tested in trial NCT06595030?

The interventions under investigation include: Active Lighting Intervention (DEVICE), Control Lighting Intervention (DEVICE).

Who is sponsoring clinical trial NCT06595030?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06595030's enrollment target sits among peer trials

101 840th of 2000 higher than 1,161 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04033497 · 101 participants · NA

    Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

  • NCT05111574 · 101 participants · Phase 2

    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  • NCT05984680 · 101 participants

    COPD Care Pathway Among Patients With Cancer

  • NCT06266299 · 101 participants · Phase 1

    A Study of KK2269 in Adult Participants With Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06595030, the US trial registry maintained by the National Library of Medicine. NCT06595030 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.